* Fulgent Genetics Inc FLGT.OQ FLGT.O is expected
to show a
rise in quarterly revenue when it reports results on August 2
for the period ending June 30 2024
* The El Monte California-based company is expected to
report a
1.8% increase in revenue to $69.066 million from $67.85 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.The company's guidance on May 3 2024, for the
period ended June 30, was for revenue of $70.934 million.
* LSEG's mean analyst estimate for Fulgent Genetics Inc is
for a
loss of 30 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $25.00, above its last closing price of $23.95.
The company's guidance on May 3 2024 for the period ended June
30 was for gross profit margin of USD40%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.32 -0.32 -0.01 Beat 96.9
Dec. 31 0001 -0.28 -0.29 0.28 Beat 197.7
Sep. 30 2023 -0.33 -0.39 Missed -18.2
Jan. 1 0001 -0.33 -0.33 -0.08 Beat
Jan. -0.43 -0.43 -0.22 Beat 48.4
1 0001
Dec. 31 2022 -0.56 -0.48 14.3
Sep. 30 2022 0.05 0.32 498.1
Jan. 1 0001 0.73 0.73 0.78 Beat 6.8
This summary was machine generated July 31 at 13:27 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)